SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
ARYx Therapeutics, Inc. (ARYX) .
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
Overall SharesGrow Score: 30/100 with 0/7 criteria passed.
SharesGrow 7-Criteria Score
✗
HEALTH
25/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — ARYX
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-1.21
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2003 |
$-16.67 |
$0.00 |
$-13.97M |
- |
| 2004 |
$-24.27 |
$0.00 |
$-20.83M |
- |
| 2005 |
$-30.73 |
$0.00 |
$-27.96M |
- |
| 2006 |
$-26.84 |
$4.74M |
$-27.33M |
-576.7% |
| 2007 |
$-8.24 |
$4.16M |
$-27.56M |
-662.8% |
| 2008 |
$-1.65 |
$19.72M |
$-31.22M |
-158.3% |
| 2009 |
$-1.21 |
$0.00 |
$-33.17M |
- |
